A PHASE I PHARMACOKINETIC STUDY OF EPOTHILONE B ANALOGUE BMS-247550 (NSC-170428D

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。在这项第一阶段研究中，BMS-247550将用于不同程度肝功能障碍的患者。根据肝功能将患者分为4组。BMS-247550将静脉输注3小时。其目的将是确定需要修改bms-247550剂量的肝脏损害程度；表征肝功能障碍对bms-247550血浆药代动力学的影响；以及确定在不同肝功能障碍水平下服用bms-247550的毒性。这是SWOG的合作小组试验。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In this Phase I study BMS-247550 will be given to patients with varying levels of liver dysfunction. Patients will be stratified into 4 groups depending on liver function. BMS-247550 will be given IV as a 3-hr infusion. The objectives will be to define levels of hepatic impairment at which dose modification of BMS-247550 is required; to characterize the effects of hepatic dysfunction on the plasma pharmacokinetics of BMS-247550; and to define toxicities associated with dosing of BMS-247550 at varying levels of hepatic dysfunction. This is a cooperative group trial from SWOG.